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Abstract
Background: Sonic hedgehog (Shh) signaling plays a crucial role in growth and patterning during embryonic development,
and also in stem cell maintenance and tissue regeneration in adults. Aberrant Shh pathway activation is involved in the
development of many tumors, and one of the most affected Shh signaling steps found in these tumors is the regulation of
the signaling receptor Smoothened by the Shh receptor Patched. In the present work, we investigated Patched activity and
the mechanism by which Patched inhibits Smoothened.
Methodology/Principal Findings: Using the well-known Shh-responding cell line of mouse fibroblasts NIH 3T3, we first
observed that enhancement of the intracellular cholesterol concentration induces Smoothened enrichment in the plasma
membrane, which is a crucial step for the signaling activation. We found that binding of Shh protein to its receptor Patched,
which involves Patched internalization, increases the intracellular concentration of cholesterol and decreases the efflux of a
fluorescent cholesterol derivative (BODIPY-cholesterol) from these cells. Treatment of fibroblasts with cyclopamine, an
antagonist of Shh signaling, inhibits Patched expression and reduces BODIPY-cholesterol efflux, while treatment with the
Shh pathway agonist SAG enhances Patched protein expression and BODIPY-cholesterol efflux. We also show that over-
expression of human Patched in the yeast S. cerevisiae results in a significant boost of BODIPY-cholesterol efflux.
Furthermore, we demonstrate that purified Patched binds to cholesterol, and that the interaction of Shh with Patched
inhibits the binding of Patched to cholesterol.
Conclusion/Significance: Our results suggest that Patched may contribute to cholesterol efflux from cells, and to
modulation of the intracellular cholesterol concentration. This activity is likely responsible for the inhibition of the
enrichment of Smoothened in the plasma membrane, which is an important step in Shh pathway activation.
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Introduction
The Hedgehog (Hh) pathway plays a crucial role in growth and
patterning during embryonic development. Consequently, defects
in Hh signaling involve human congenital malformations and
disorders such as holoprosencephaly (HPE) and Gorlin’s syndrome
[1,2,3,4]. In adults, recent studies suggest a role of this pathway in
stem cell self-renewal and in the mobilization of endogenous stem
cells for tissue repair and regeneration following injury and disease
[5,6,7]. Mutations in the Hh pathway components have been
identified in basal cell carcinoma, medulloblastoma, and rhabdo-
myosarcoma, and aberrant activity of the pathway has been shown
to be involved in the development of many other tumors (lung,
esophagus, stomach, pancreas, biliary tract, breast, prostate, and
brain) [8]. Many of these tumors contain cancer stem cells which
retain self-renewal properties, representing a never-ending reser-
voir for the maintenance of the tumor mass [8].
In Hh-secreting cells, newly made Hh protein undergoes auto-
processing and lipid modification, resulting in the secretion of a
fully active N-terminal Hh signaling domain (HhN) of 19 kDa
modified by a palmitoyl group and a cholesterol molecule,
respectively, in its N- and C-termini [9]. Secreted HhN is able
to act over a long range by a mechanism that is not yet completely
understood. The different HhN proteins (ShhN, IhhN, and DhhN)
are secreted at various stages of development, and initiate signaling
in receiving cells by binding to the Hh-receptor Patched (Ptc). In
vertebrates, the interaction between HhN and Ptc relieves the
inhibition of the signal transducer Smoothened (Smo), which is
then re-localized and enriched at the plasma membrane and
activated. This triggers a cascade of downstream events that
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transcription through the zinc finger transcription factors glio-
ma-associated oncogenes (Gli) [1]. In the absence of secreted Hh,
the pathway is turned off due to the inhibition exerted by Ptc on
Smo. Ptc, Smo, Su(Fu), and Gli have been detected in primary
cilia, which are present in nearly all vertebrate cells to transmit
information from the environment [10,11]. Several components of
the transport machinery required for the assembly and mainte-
nance of cilia were reported to be essential for Hh signaling
[12,13,14].
The regulation of Smo activation by Ptc appears to be one of
the most disrupted steps in the Hh pathway related to human
cancers, and the mechanism by which Ptc represses Smo remains
unresolved. Taipale and co-workers showed in 2002 that Ptc
inhibits Smo sub-stoichiometrically, thereby avoiding direct
interaction between Ptc and Smo [15]. Several small molecules
modulate Hh signaling through direct binding to Smo, and some
Smo antagonists are in clinical trials for treating tumors [8,16].
Moreover, Smo would be repressed by molecules such as vitamin
D3 [17], and activated by oxysterols [13,18,19] and phosphatidy-
linositol 4-phosphate [20]. On the basis of these observations and
the sequence homology of Ptc with bacterial transmembrane
transporters, Ptc has been proposed to function as a pump that
would change the concentration of a small molecule involved in
Smo activation or inhibition [15,21]. However, the transport
activity of Ptc has not yet been demonstrated, the identity of the
small molecule responsible for the physiological Ptc/Smo
regulation is still unknown, and the mechanism by which Ptc
regulates Smo activation remains to be elucidated.
In the present study, we report that Ptc is likely involved in the
efflux of cholesterol from cells, and we propose that this activity
may contribute to Smo repression.
Materials and Methods
Cell cultures
NIH 3T3 mouse fibroblast cells (ATCC CRL-1658) were grown
in DMEM medium (Invitrogen) supplemented with 10% fetal
bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomy-
cin, at 37uC in a 5% CO2/95% air water-saturated atmosphere.
Depending on the experiment, 30 nM ShhN, 10 mM purmorpha-
mine (Alexis Biochemicals), 10 mM cyclopamine (Jentaur), or
10 mM cholesterol (Sigma) were added to the culture medium
when the cells were 80% confluent.
K699 S. cerevisiae yeast strain (Mata, ura3, and leu 2–3)
transformed with YEpPMAhPtc-MAP, YEpPMAhSmo-MAP, or
YEpPMAmMyo-MAP expression vector were grown as described
[22] at 18uC until OD600=5–7.
RNA isolation, reverse transcription and quantitative RT-
PCR (qRT-PCR)
Total cellular RNA was extracted from NIH 3T3 cells using the
TRIzol reagent according to the manufacturer’s instructions
(Invitrogen). One mg of total RNA from control or treated samples
were reverse-transcripted with 50 nmol of oligo (dT) using
M-MLV reverse transcriptase (RT) (Invitrogen) following the
manufacturer’s protocol. Real-time quantitative RT-PCR analyses
were performed with a Stratagene Mx3000p system and Mesa
Green qPCR MasterMix Plus for SYBRH (RT-SY2X-
03+WOULR, Eurogentec). Briefly, 100 ng of reverse-transcripted
RNA from each sample was mixed with appropriate concen-
trations of tested gene primers and the Mesa Green qPCR
MasterMix. Primers were designed using Primer3 input patched1
sense AGCTGTGGGTGGAAGTTGGT, antisense TCCGTGA-
TAAGTTCCCCTGA, 18S mRNA sense CGCCGCTAGACG-
TAGAATTCT, antisense CATTCTTGGCAAATGCTTTGC. PCR
amplifications were carried out as follows: 10 min at 95uC; 45 cycles
(30 s at 95uC, 60 s at 60uC, and 60 s at 72uC). For each condition,
expression was quantified in duplicate, and 18S mRNA was used as
the endogenous control in the comparative cycle threshold (CT)
method. Data were expressed as relative expression ratio.
NIH 3T3 membrane preparation
All steps were performed at 4uC. NIH 3T3 cells were grown on
100-mm Petri dishes to confluence, collected, centrifuged, washed
two times with PBS and one time with water, and re-suspended in
hypotonic buffer containing 50 mM Tris-HCl, pH 7.5, 1 mM
EDTA, and proteases inhibitor cocktail (PIC, Roche). After
10 min on ice, the cells were broken by passages through a syringe.
Cellular remains were pelleted for 10 min at 430 g and the
supernatant was centrifuged for 30 min at 20,000 g to collect
heavy membranes, essentially plasma membranes.
NIH 3T3 total extract preparation
Cells were collected, pulled down at maximum speed for a few
seconds, washed one time with PBS, and then re-suspended in
RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM
PMSF, 1 mM EDTA, 1% Triton, 1% sodium deoxycholate, 0.1%
SDS, PIC). Unsolubilized cells and cellular remains were pelleted,
and the supernatants were collected.
Protein quantification
Protein concentrations were determined by the Bradford
method using a Bio-Rad kit.
Purification of ShhN protein
Mouse fibroblast L cells (LTK-P2 cells obtained from RIKEN
Cell Bank (RCB0208), Japan) stably expressing the active amino-
terminal domain of the murine Shh protein corresponding to
amino acids 25 to 198 (ShhN) were grown in suspension, and
ShhN protein was purified from 5 L of conditioned culture
medium as described previously [22]. The ability of purified ShhN
to activate the Hh pathway was assessed on C3H10T1/2 cells
(from ATCC) by alkaline phosphatase activity and Gli responsive
element activity as described previously [22].
Purification of hPtc and mMyo
Yeasts expressing human Ptc (hPtc) or mouse Myodulin (mMyo)
were cultured until an OD600 of 7 was reached. Membranes were
prepared and solubilized with 20 mM dodecyl-b-D-maltoside
(DDM, Calbiochem). hPtc and mMyo were purified on a
calmodulin-Sepharose resin (Amersham) as described previously
[22,23,24].
Generation of polyclonal antiserum to the mouse
Patched
A DNA encoding part of the carboxyl-terminal domain of the
mouse Patched (residues 1321–1427) was amplified by PCR and
fused to GST in pGEX-4T-1. The fusion protein was purified and
antiserum was produced in a rabbit as previously described [25].
The antiserum (Ab130) has been tested on HEK293 cells (from
ATCC CRL-1573) transiently transfected with mouse Ptc cDNA
and was shown to be highly specific for Ptc (Fig. S1).
SDS-PAGE and Western blotting
Protein samples were separated on 8% SDS-PAGE and trans-
ferred to nitrocellulose membranes (Amersham) using standard
Patched Is Involved in Cholesterol Efflux
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(20 mM Tris-HCl (pH 7.5), 450 mM NaCl, 0.1% Tween-20, and
4% non-fat milk), membranes were incubated overnight at 4uC
with mouse monoclonal anti-HA antibodies (dilution 1:20 [22]),
or for 2 h at room temperature with rabbit anti-Ptc antiserum
(Ab130) (1:1000) or rabbit polyclonal anti-Smo antibodies
(1:3000), and washed twice in blocking buffer before incubation
for 2 h at 4uC with polyclonal anti-mouse (1:5000) or polyclonal
anti-rabbit (1:3000) immunoglobulin coupled to horseradish
peroxidase (Dako). Detection was with an ECL kit (Millipore)
and the Fusion FX7 systemH (Vilber-Lourmat).
Gas chromatography analysis
NIH 3T3 cells were cultured to 80–90% confluence, and
30 nM of pure ShhN protein was added to the cell medium 24 h
before harvesting. Total extracts were prepared and the lipids
were extracted [26]. Lipids were saponified with 1 M methanolic
KOH for 16 h at room temperature under argon in the dark. The
unsaponified fraction was extracted with tert-butyl methyl ether.
An aliquot of this fraction was converted to the trimethylsilyl ether
derivative to quantify cholesterol by gas chromatography (GC)
using a 5890 Series II Hewlett-Packard GC (Agilent) equipped
with a flame ionization detector and a DB5-MS fused silica
capillary column (30 m60.25 mm i.d., 0.25 ı `m, J&W Scientific)
using 5a ´-cholestane as the internal standard. The chromatograph-
ic data were processed using Galaxie software (Varian).
BODIPY-cholesterol fluorescence measurements
BODIPY-cholesterol was synthesized as described previously
[27] and afterwards was purchased (TopFluor-Cholesterol, Avanti
Polar Lipids). Stock solutions were prepared at 5 mM in DMSO.
NIH 3T3 cells were cultured in 24-well plates and loaded with
2.5 mM of BODIPY-cholesterol in culture medium for 2 h at
37uC. Cells were rinsed twice with physiological buffer (140 mM
NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgSO4, 5 mM glucose,
20 mM HEPES, pH 7.4), and incubated with the same buffer
supplemented or not with 30 nM of ShhN for 1 h at 37uC under
shaking at 50 rpm. The cell supernatant was centrifuged for 5 min
at 6800 g, and the BODIPY fluorescence intensity in the
supernatants was measured in a Plate reader (Fluostar, Labtech)
(excitation 490610 nm; emission 520620 nm). For fluorescence
microscopy observations, NIH 3T3 cells were cultured on glass
plates, loaded with 2.5 mM BODIPY-cholesterol for 2 h at 37uC,
rinsed, and incubated with physiological buffer supplemented or
not with 30 nM ShhN at 37uC for 30 min. Cells were rinsed with
phosphate buffer (pH 7.4), fixed with 4% paraformaldehyde for
10 min, and observed using a deconvolution microscope (DeltaVi-
sion) equipped with an objective 60x/1.4 oil. BODIPY fluores-
cence was analyzed using Image J software.
S. cerevisiae over-expressing human Ptc or mouse Myodulin were
grown at 18uC until an OD600 of 7, washed with cold water, and
re-suspended at an OD600 of 10 in Hepes-NaOH buffer (pH 7.0)
supplemented or not supplemented with 5 mM of 2-deoxy-D-
glucose. Cells were incubated with 5 mM BODIPY-cholesterol or
5 mM BODIPY-cyclopamine (BODIPY-CPN, Toronto Research
Chemicals Inc) for 2 h at room temperature on a rotating wheel
and washed quickly, re-suspended in the same buffer, and
incubated at room temperature on the rotating wheel. Aliquots
were centrifuged for 1 min at 18,000 g immediately after re-
suspension and the pellets were solubilized with SDS to measure
the BODIPY-cholesterol loaded into yeast. The rest of the samples
were centrifuged for 1 min at 18,000 g, 30 s, 3, 5 or 20 min after
re-suspension, and the resulting supernatants were collected to
measure the BODIPY-cholesterol efflux. The BODIPY fluorescence
intensity was measured in the Plate reader (Fluostar, Labtech)
(excitation 490610 nm; emission 520620 nm). For all BODIPY-
cholesterol efflux experiments, the results were analyzed using the
Student’s t test where significance is attained at p,0.05.
Surface plasmon resonance (SPR) experiments
SPR experiments were performed on a Biacore 3000 instrument
(Biacore/GE Healthcare Uppsala, Sweden). A stock solution of
thiocholesterol (Sigma) in DMSO (1 mg/mL) was prepared and
diluted 1:50 in sodium borate buffer, pH 8.5, for covalent thiol-
coupling to the flow cell 2 (fc2) of a CM5 sensor chip. The flow cell
1 (fc1) was activated without thiocholesterol and used as a
reference for nonspecific binding. Experiments with purified
proteins were performed at 10uC. Purification buffer containing
50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10% glycerol, and
2 mM of DDM was used as the running buffer. Purified proteins
(50 mL) were injected on fc1 and fc2 at a flow rate of 10 mL/min,
and the differences between sensorgrams on fc2 and fc1 were
recorded. The sensor chip surface was regenerated twice with
20 mL of 50 mM NaOH and 0.05% SDS injected at 20 mL/min.
For inhibition assays, purified hPtc was incubated with increasing
concentrations of pure ShhN protein before injection onto fc1 and
fc2. The inhibition percentage of the binding response was plotted
vs. ShhN concentration, and the apparent Ki value was
determined from non-linear regression curve fitting using Origin
software.
Results
Cholesterol concentration variations affect Smoothened
enrichment in the plasma membrane
To investigate the effect of cholesterol modulation on the Hh
signaling, we used mouse fibroblasts NIH 3T3, which do not
synthesize Shh but are highly responsive to Shh and have been
widely used to study the Hh pathway [1,13,28,29,30]. We purified
the amino-terminal domain of the murine Shh protein without
cholesterol and palmitate modification (ShhN), and showed that
purified ShhN fully activates the Hh signaling [22]. In the absence
of ShhN, Smo is inactivated and cleared from the cell surface via
endocytosis [31,32]. Therefore, Smo is only slightly present in the
plasma membrane, as shown in Fig. 1A, lane 1. When added to
the culture medium, ShhN binds to Ptc and rapidly induces Ptc
internalization and degradation (Fig. 1A, lane 3). After 24 h, a
dual effect of ShhN is observed on Ptc protein: enhancement of Ptc
expression induced by Hh pathway activation and degradation of
Ptc due to the presence of ShhN in the culture medium. This
explains why the Ptc signal at the plasma membrane increases in
comparison with the Ptc signal after 6 h exposure to ShhN but is
still lower than that in non-treated cells (Fig. 1A, lane 4). The
clearance of Ptc allows Smo enrichment in the plasma membrane
(Fig. 1A, lane 2), without changes in Smo total amount (Fig. 1B)
[10,13,33,34,35]. Smo enrichment in the plasma membrane, and
more particularly at the primary cilia in vertebrates, is correlated
with Hh signaling activation [10,12,29]. We incubated fibroblasts
NIH 3T3 with ShhN, cholesterol, the Hh pathway agonist
purmorphamine, or with ShhN protein plus lovastatin, an
inhibitor of cholesterol biosynthesis [36], and we examined the
effects on Smo enrichment in the plasma membrane (Fig. 1C).
Remarkably, the amount of endogenous Smo at the cell surface
increases after incubation of cells with cholesterol in a comparable
way to when cells are incubated with ShhN protein or with the
Smo agonist purmorphamine (Fig. 1C, lanes 2, 3, 4). On the other
hand, addition of lovastatin in the culture medium strongly inhibits
Smo enrichment in the plasma membrane by ShhN (Fig. 1C, lane
Patched Is Involved in Cholesterol Efflux
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allows Smo enrichment in the plasma membrane; in contrast, the
decrease in intracellular cholesterol concentration induced by
addition of lovastatin to the culture medium containing ShhN
prevents Smo enrichment in the plasma membrane. This suggests
that the intracellular cholesterol concentration may be critical for
Smo enrichment in the plasma membrane. Smo agonists such as
purmorphamine turn on the expression of Hh pathway target
genes like Ptc (Fig 1D, left panel, lane 2); however, we did not
observe a boost of Ptc expression in cells treated with cholesterol
(Fig. 1D, left panel, lane 3). RT PCR analysis (Fig. 1D, right panel)
shows that cholesterol does not significantly affect Ptc RNA
expression; in contrast, purmorphamine enhances it more than 3
fold, in good agreement with the Western blot analysis. It also
shows that lovastatin treatment prevents the activation of Ptc RNA
expression by ShhN. These results suggest that cholesterol is
necessary for Smo enrichment in the plasma membrane but is not
sufficient for Hh pathway activation.
Figure 1. Effect of Hh signaling modulators on Ptc and Smo. ShhN acts on the levels of Ptc and Smo at the plasma membrane (A). Enriched
plasma membrane fractions were prepared from NIH 3T3 cells (control and cells treated with 30 nM ShhN for 1, 6, or 24 h) for immunoblotting with
antibodies against Ptc or Smo. ShhN does not modify the Smo total amount (B). Total extract from NIH 3T3 cells treated or not treated with 30 nM
ShhN for 6 h were prepared for immunoblotting with antibodies against Smo. Cholesterol enhances Smo enrichment at the plasma membrane (C).
Enriched plasma membranes fractions were prepared from NIH 3T3 cells (control and cells treated for 6 h with 30 nM ShhN, 6 h with 10 mM
purmorphamine (a Smo agonist), 3 h with 2.5 mM cholesterol, or 6 h with 30 nM ShhN plus 10 mg/mL of the cholesterol biosynthesis inhibitor
lovastatin) for immunoblotting with antibodies against Smo. Contrary to the Hh signaling activators such as purmorphamine, cholesterol does not
enhance Ptc expression (D). NIH 3T3 cells were treated for 48 h with 10 mM purmorphamine, with 2.5 mM cholesterol, or with 30 nM ShhN plus
10 mg/mL of lovastatin. Enriched membrane fractions were prepared for immunoblotting with antibodies against Ptc and the Ptc signal was
quantified using Image J software from 3 independent experiments (left panel). RT PCR analysis were performed and quantified using 18S mRNA as
an endogenous control (right panel).
doi:10.1371/journal.pone.0023834.g001
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In order to understand the link between cholesterol and Hh
signaling, we used a fluorescent derivative of cholesterol, BODIPY-
cholesterol [27]. This cholesterol derivative has been shown to
closely mimic the membrane partitioning and trafficking of
cholesterol, and, because of its excellent fluorescent properties, to
enable direct monitoring of sterol movement by time-lapse imaging
[37]. Fibroblasts treated with BODIPY-cholesterol show an
enrichment of Smo in the plasma membrane similar to that
induced by ShhN treatment (Fig. 2A), indicating that this probe
behaves like cholesterol in Hh signaling. NIH 3T3 fibroblasts were
grown in 24-well plates, loaded with BODIPY-cholesterol, rinsed,
and incubated with physiological buffers with and without ShhN
protein. The BODIPY fluorescence measured in the supernatants
after 1 h was significantly lower in wells where ShhN protein was
added compared to wells that did not contain ShhN (mean decrease
4566%) (Fig. 2B). The observation of cells by fluorescence
microscopy shows that the content of BODIPY-cholesterol is
significantly higher in cells incubated with a buffer containing ShhN
protein (Fig. 2 C, D). These results are in good agreement with the
data obtained by gas chromatography which show that cells treated
with ShhN contain a higher intracellular cholesterol concentration
compared with untreated cells (Table 1), and suggest that ShhN
treatment reduces cholesterol efflux from cells. ShhN protein has
Figure 2. BODIPY-cholesterol efflux from fibroblasts is affected by ShhN. BODIPY-cholesterol induces the accumulation of Smo in the
plasma membrane as cholesterol (A). Plasma membrane enriched fractions from control NIH 3T3 (A, lane 1), NIH 3T3 treated for 6 h with 30 nM ShhN
(A, lane 2), and NIH 3T3 treated for 3 h with 2.5 mM BODIPY-cholesterol (A, lane 3) were prepared for immunoblotting with antibodies against Smo.
ShhN decreases BODIPY-cholesterol efflux (B). NIH 3T3 were cultured in 24-well plates, incubated for 2 h with 2.5 mM BODIPY-cholesterol, and rinsed.
Physiological buffer with or without 30 nM ShhN was added to the wells, and the BODIPY fluorescence intensity of the supernatants was measured
after 1 h. The mean 6 SEM of 8 independent experiments is presented (p=0.006). The BODIPY fluorescence intensity that remained in NIH 3T3 after
1 h efflux was observed using Delta vision fluorescent microscope (C) and quantified using Image J software (D). The results show that cells treated
with ShhN retain more BODIPY-cholesterol than untreated cells. Immunoblotting with antibodies against Ptc of enriched plasma membrane fractions
(E, upper panel) and total extracts (E, lower panel) from NIH 3T3 in the presence or absence of 30 nM ShhN show that the level of Ptc protein is
decreased by ShhN treatment. The Ptc signal was quantified using Image J software from 3 independent experiments and untreated cells as control.
doi:10.1371/journal.pone.0023834.g002
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degradation [13,38,39]. Despite the weakness of the signals due to
the low basal expression of Ptc, we observed that ShhN treatment
indeeddecreased the amountofPtcboth inmembranepreparations
(Fig. 2 E, upper panel) and total extracts (Fig. 2 E, lower panel) to
4464% of Ptc signal obtained with untreated fibroblasts.
Treatment of fibroblasts with Hh pathway modulators
modify cholesterol efflux
NIH 3T3 fibroblasts were treated for 48 h with cyclopamine
(CPN, a well-known antagonist of the Hh pathway [40]) or SAG (a
well-known Hh pathway agonist [19]), before incubation with
BODIPY-cholesterol. After rinsing, the cells were incubated for
1 h in physiological buffer. We observed that the BODIPY
fluorescence in the supernatants was significantly lower in wells
containing cells treated with CPN compared to wells containing
untreated cells (mean fluorescence decrease of 3566%) (Fig. 3A),
and significantly higher in wells containing cells treated with SAG
compared to wells containing untreated cells (mean fluorescence
increase of 68%) (Fig. 3C). These results indicate that treatment of
cells with the antagonist CPN decreases BODIPY-cholesterol
efflux, whereas treatment with the agonist SAG enhances
BODIPY-cholesterol efflux. We also observed that Ptc expression
level was reduced to 45612% in NIH 3T3 cells treated with CPN
(Fig. 3B) and enhanced to 205635% in NIH 3T3 cells treated
with SAG (Fig. 3D) in comparison with Ptc signal obtained with
untreated cells. The binding of CPN to Smo inhibits Hh signal
transduction and represses the expression of Hh target genes such
as Ptc. On the other hand, the binding of SAG to Smo activates
Hh signal transduction and the expression of Ptc.
The results obtained with NIH 3T3 fibroblasts show that
modulating the Hh signaling and Ptc protein levels has an effect on
intracellular cholesterol content and BODIPY-cholesterol efflux.
To demonstrate the link between Ptc and cholesterol efflux, we
over-expressed human Ptc in yeast and analyzed the effect of Ptc
expression on the efflux of cholesterol from yeast cells.
Human Ptc expressed in yeast increases the efflux of
cholesterol
We recently developed the functional expression of the human
protein Ptc (hPtc) in the plasma membrane of S. cerevisiae with a
multitag affinity purification sequence (MAP) fused in its C-
terminus (Fig. 4A, lane 1). We previously showed that hPtc was
able to bind its ligand ShhN both in yeast membranes and in
surfactant suspension after purification [22,41]. Yeast expressing
the non-relevant membrane protein Myodulin (Myo) [42] (used as
control) and yeast expressing hPtc were loaded with BODIPY-
Table 1. Shh increases cell cholesterol concentration.
Experiment Cholesterol (mg/mg prot) Variation (%)
Control + Shh Shh/control
1 0.0061 0.0083 +36.13
2 0.0157 0.0177 +12.58
3 0.0156 0.0190 +21.57
NIH 3T3 cells were treated with or without 30 nM ShhN and the cholesterol in
cell extracts was quantified by gas chromatography in three independent
experiments.
doi:10.1371/journal.pone.0023834.t001
Figure 3. Fibroblast treatment with Hh pathway modulators modifies BODIPY-cholesterol efflux. NIH 3T3 fibroblasts were cultured in
24-well plates for BODIPY-cholesterol efflux measurements (A and C) or in 100-mm diameter plates for membrane preparations and immunoblotting
(B and D), and treated for 48 h with 10 mM cyclopamine (CPN) (A and B) or 100 nM SAG (C and D). CPN and SAG are antagonists and agonists of the
Hh pathway, respectively. The histograms presented in A and C are the mean 6 SEM of 3 independent experiments (p=0.04). The Ptc signals from
immunoblots presented in B and D and other independent experiments were quantified using Image J software and untreated cells as control.
doi:10.1371/journal.pone.0023834.g003
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30 s, and for 3, 5, and 20 min. We observed that the BODIPY
fluorescence intensity in the supernatants of yeast expressing hPtc
was higher than that of yeast expressing Myo (Fig. 4B). We then
measured the BODIPY-cholesterol fluorescence intensity present
in the supernatants 20 min after re-suspension in nine indepen-
dent experiments. We observed that the presence of hPtc
significantly increased BODIPY-cholesterol efflux (about 88%),
while the content of BODIPY-cholesterol incorporated in yeast
expressing Myo or hPtc were comparable (Fig. 4C). We then
measured BODIPY-cholesterol efflux in the presence of 2-deoxy-
D-glucose in order to inhibit ABC transporters, and we obtained
comparable results (Fig. 4D), suggesting that the BODIPY-
cholesterol efflux observed in yeast expressing hPtc is not linked
to ABC transporter activity. We also carried out BODIPY-
cholesterol efflux measurements on yeast cells over-expressing
human Smo (hSmo) [24]. We observed that the expression of hSmo
has no effect on BODIPY-cholesterol efflux, which is comparable to
that measured in yeast expressing Myo and lower than that
measured in hPtc-expressing yeast (Fig. 4D). Similar experiments
were carried out with another BODIPY-modified cholesterol
related molecule (BODIPY-cyclopamine), and on yeast cells treated
withcyclopaminebeforeincubation with BODIPY-cholesterol. The
BODIPY fluorescence intensity measured in the supernatants
20 min after incubation with BODIPY-cyclopamine and re-
suspension was not significantly different with yeast expressing hPtc
than with yeast expressing Myo (Fig. S2). CPN treatment did not
prevent BODIPY-cholesterol efflux enhancement observed in yeast
expressing Ptc (Fig. S3). These observations indicate that CPN does
not have a direct effect on BODIPY-cholesterol efflux from
fibroblasts. Furthermore, these results strongly suggest that human
Ptc contributes to BODIPY-cholesterol efflux when over-expressed
in yeast.
Ptc binds to cholesterol
We then examined the ability of hPtc to bind to cholesterol
using Surface Plasmon Resonance (SPR). Myo and hPtc were
purified from yeast, and injected onto a Biacore sensor chip in
which one flow cell (fc) was covalently coupled to thiocholesterol
and another was just activated without thiocholesterol for non-
specific binding. The sensorgrams resulting from the difference
between the binding on the thiocholesterol-coupled fc and the
control one showed a clear binding of hPtc to cholesterol coupled
on the fc in comparison with Myo (Fig. 5A). Incubation of hPtc
with pure ShhN protein prior to injection onto the sensor chip
inhibited the binding of hPtc to cholesterol in a ShhN
concentration-dependent manner, while ShhN had no effect when
incubated with Myo prior to injection (Fig. 5A). The apparent
inhibition constants (Ki) calculated for three independent exper-
iments were between 0.8 and 1 nM (Fig. 5B), which corresponds
to the apparent affinity of ShhN for hPtc [15,41]. These results
suggest that hPtc binds to cholesterol, and that the interaction of
ShhN with hPtc partially prevents this binding, probably by
inducing a conformational change in Ptc before its internalization
and degradation in cells.
Discussion
Since the first publication on cholesterol balance in mice [43], it
is clear that cholesterol homeostasis is one of the most intensely
Figure 4. hPtc over-expressed in S. cerevisiae induces cholesterol efflux. Membranes from human Ptc (hPtc) expressing yeast (A, lane 1) and
mouse myodulin (Myo) expressing yeast (used as control) (A, lane 2) were prepared for immunoblotting with antibodies against hemagglutinin (A).
Yeast over-expressing Myo (control) or hPtc were incubated for 2 h with 2.5 mM BODIPY-cholesterol, washed, re-suspended in buffer, and then
centrifuged for 30 s and for 3, 5, or 20 min. Then, the fluorescence intensity of the supernatants was measured (B). The BODIPY fluorescence intensity
of the supernatants 20 min after resuspension and in yeast after loading and washing was measured in 9 independent experiments. The mean values
6 SEM are presented (p=0.002) (C). The same experiments were carried out with yeast expressing human Smo and in the presence of 5 mM 2-deoxy-
D-glucose to inhibit ABC transporters during BODIPY-cholesterol loading and efflux (D).
doi:10.1371/journal.pone.0023834.g004
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biosynthesis induce severe developmental malformations in a
multitude of diseases such as Smith-Lemli-Opitz syndrome (SLOS),
desmosterolosis, and lathosterolosis. SLOS and lathosterolosis are
characterized by accumulation of the cholesterol precursors 7-
dehydrocholesterol and lathosterol, and decreased cholesterol
concentration, which also impairs the Shh pathway at the level of
Smo [21]. Holoprosencephaly (HPE), the most severe form of
SLOS, results from impairment of Shh signaling secondary to
abnormal cholesterol metabolism [45,46]. These observations and
studies reporting the effect of cholesterol or oxysterols on the Hh
pathway [18] indicate that cholesterol or its derivatives are impor-
tant components for the function of the Shh signaling cascade. The
question is: how does cholesterol intervene in the Hh pathway?
We report here that activation of Hh signaling with the purified
Shh N-terminal active domain increases the endogenous intracel-
lular concentration of cholesterol in mouse NIH 3T3 fibroblasts,
and that adding cholesterol to the culture medium induces Smo
enrichment in the plasma membrane, as does ShhN or the Smo
agonist purmorphamine. In contrast, treatment of cells with an
inhibitor of the cholesterol synthesis (lovastatin) prevents Smo
accumulation in the plasma membrane by ShhN. These results
suggest that Smo enrichment in the plasma membrane, which is a
critical step in Hh signal transduction [10,13,33,34], depends on
the intracellular concentration of cholesterol. This hypothesis is in
good agreement with studies reporting activation of the Hh
pathway by oxysterols [13,18,19] and inhibition of the cellular
response to Hh protein stimulation by genetic or pharmacological
sterol depletion [21,45,47]. However, we did not observe an
increase of Ptc protein or RNA expression after cholesterol treat-
ment, contrary to purmorphamine treatment (which enhanced Ptc
RNA and protein expression by approximately 3 fold). This was
expected for an agonist of Hh signaling since the Ptc gene is one of
the Hh target genes. Moreover, we observed that decreasing
cholesterol concentration by lovastatin treatment prevents the
activation of Ptc expression by ShhN, which is surely a conse-
quence of inhibition of Smo accumulation at the plasma
membrane. These results suggest that intracellular cholesterol,
by promoting Smo enrichment in the plasma membrane, is
necessary for Hh signal transduction but is not sufficient for Hh
pathway activation. Our results are in full agreement with those of
Rohatgi and co-workers, who reported that a second step is
required after Smo enrichment in cilia for full Hh pathway
activation [29], and with those of Corcoran and Scott, who
reported that cholesterol or specific oxysterols are required for Shh
signal transduction in medulloblastoma cells and that these sterols
would act at the level of Smo [18].
In the second part of this report, we sought to demonstrate that
Ptc could be responsible for the reduction of the cholesterol
concentration in the environment of Smo by pumping cholesterol
out of the cell. Therefore, we used BODIPY-cholesterol, a
fluorescent cholesterol derivative in which the BODIPY moiety is
linked to C-24 of the cholesterol side chain [27]. This probe was
found to mimic endogenous cholesterol partitioning into liquid-
ordered domains in model membranes and allowed visualization
of trafficking of cholesterol in living cells [37]. We observed that
the presence of ShhN causes an inhibition of BODIPY-cholesterol
efflux from NIH 3T3 fibroblasts. We also noted a decrease of the
amount of Ptc protein in these cells, which is in good agreement
with studies reporting that ShhN induces Ptc internalization and
degradation [13,33,34,48]. Furthermore, treatment of NIH 3T3
fibroblasts with the Smo antagonist cyclopamine inhibits Ptc
expression, which was expected since the Ptc gene is one of the
targets of the Hh pathway, and reduces BODIPY-cholesterol
efflux. Therefore, we thought that the decrease of BODIPY-
cholesterol efflux observed with fibroblasts treated with ShhN or
with cyclopamine could be due to the clearance of Ptc from the
plasma membrane. Remarkably, treatment of fibroblasts with the
Hh pathway agonist SAG, which enhances Ptc protein expres-
sion, clearly increases BODIPY-cholesterol efflux, and over-
expression of human Ptc in yeast also significantly enhances
BODIPY-cholesterol efflux from yeast. Finally, we showed that
Ptc is able to bind cholesterol using purified hPtc and surface
plasmon resonance measurements. All of these results strongly
Figure 5. Purified Ptc binds to cholesterol. Human Ptc and mouse Myodulin were purified from S. cerevisiae. Proteins were injected onto the
flow cell 2 (fc2) covalently coupled with thiocholesterol and the flow cell 1 (fc1) used as control of a Biacore sensor chip CM5. The difference between
the sensorgrams recorded on fc2 and fc1 are reported (A). The sensorgrams recorded with Ptc (black lines) and Myodulin (grey lines) before (full lines)
and after (tear lines) incubation with 15 nM pure ShhN show that Ptc binds to cholesterol coupled onto the sensor chip and that ShhN partially
inhibits this binding. Sensorgrams were recorded with Ptc incubated with increasing concentrations of pure ShhN (1.5, 7.5, 15 nM) before injection,
and the% cholesterol binding inhibition was plotted vs. ShhN concentration. The curves obtained from 3 independent experiments were fitted on an
exponential curve using Origin software, giving Ki values between 0.8 and 1.0 nM (B).
doi:10.1371/journal.pone.0023834.g005
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cells.
Moreover, the sequence similarities of Ptc with the Niemann-
Pick disease type C1 protein NPC1, which is involved in binding
and transport of cholesterol [49,50,51,52], support our hypothesis
of the involvement of Ptc in cholesterol binding and transport. The
Ptc sequence possesses a sterol-sensing domain (SSD) which is a
phylogenetically conserved domain shared by several classes of
proteins having key roles in different aspects of cholesterol
homeostasis, such as NPC1 [53], and is essential for Smo
repression in Drosophila and vertebrates [54,55]. Indeed, blocking
Ptc SSD activity in Drosophila not only causes endosomal lipid
accumulation but also alters the trafficking of Smo from
endosomes [56].
From the results reported here, we propose the following
regulation mechanism between Ptc and Smo (Fig. 6). In the
absence of ShhN, Ptc is present in the plasma membrane at or
near the primary cilium where it contributes to cholesterol efflux
from the cell. This decreases intracellular cholesterol concentra-
tion and inhibits Smo, which is cleared from the cell surface via
endocytosis [31,32]. Interaction of ShhN with Ptc induces Ptc
internalization and inhibits cholesterol efflux. The intracellular
concentration of cholesterol increases, allowing the enrichment of
Smo at the cilium.
The involvement of Ptc in cholesterol transport and the Ptc-
dependent Smo regulation mechanism proposed here are
consistent with the Hh signaling impairment caused by decreased
intracellular cholesterol levels observed in congenital malforma-
tions such as SLOS and lathosterolosis [21]. Defective regulation
of cholesterol biosynthesis could further aggravate impaired Hh
signaling in holoprosencephaly [46]. It is also consistent with
recent data suggesting that binding of Hh to Ptc de-repressed the
levels of phosphatidylinositol 4-phosphate (PI-4P) which in turn
promoted Smo activation [20], since cholesterol has been shown to
modulate PI-4P synthesis [57].
Finally, several studies have reported that addition of cholesterol
biosynthesis inhibitors such as lovastatin to classical chemotherapy
enhances the efficacy of treatment for some tumors [58].
Interestingly, we noted that statin-sensitive tumors present an
aberrant Hh pathway activation. Our results could explain how
the decreased cholesterol concentration induced by statins may
affect Smo enrichment at the cell surface, and subsequently inhibit
the Hh pathway and the proliferation of cancer cells. Thus
targeting the Hh pathway in combination with classical chemo-
therapy may be a promising therapeutic strategy for treatment of
Hh related tumors.
Supporting Information
Figure S1 Ab130 antiserum specificity. Total extracts from
HEK293 cells transiently transfected with mouse Ptc cDNA (1) or
empty vector (2) were western blotted with antiserum Ab130. The
bands that appear in lane 1 correspond to monomeric and
multimeric forms of Ptc. These bands are not present when
western blotting was carried out using Ab130 serum incubated
with the polypeptide used for immunization (lane 3), showing that
Ab130 antiserum is a specific anti-Ptc antibody.
(TIF)
Figure S2 Ptc specifically enhances cholesterol efflux.
Yeast expressing the non-relevant membrane protein Myo (used as
control) and yeast expressing human Ptc were incubated with
2.5 mM BODIPY-cholesterol or 2.5 mM BODIPY-cyclopamine
(BODIPY-CPN) for 2 h, and the BODIPY fluorescence intensity
was measured in the supernatants 20 min after washing and
resuspension. The presence of hPtc increased BODIPY-cholesterol
efflux by 80% vs. an increase of BODIPY-CPN efflux by only
20%.
(TIF)
Figure S3 Cyclopamine has no effect on BODIPY-
cholesterol efflux in yeast. Yeast expressing human Ptc were
treated with 10 mM cyclopamine before incubation with 2.5 mM
BODIPY-cholesterol for 2 h. The BODIPY fluorescence intensity
was measured in the supernatants 20 min after washing and
resuspension. Cyclopamine treatment did not affect BODIPY-
cholesterol efflux.
(TIF)
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